Drugs / S-488211
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04316689 | Jul 2019 → Sep 2021 | esophageal cancer, head and neck cancer, lung cancer, mesothelioma +1 | Shionogi | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04106115 | Mar 2022 → Mar 2027 expected | urinary bladder cancer | University College, London | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-488211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04316689 ↗ |
| Modality | Vaccine | “S-488210/S-488211 (a 5-peptide cancer vaccine)” NCT04106115 ↗ |
| Route | Subcutaneous | “subcutaneous injections of S-488210/Montanide and S-488211/Montanide” NCT04106115 ↗ |